Business
LifeStance Reports Fourth Quarter and Full Year 2025 Results
Announces $100 Million Share Repurchase Program SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the
About this update from Lifestance Health Group, Inc.
[{"type":"text","content":"Announces $100 Million Share Repurchase Program\nSCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. (All results compared to prior-year comparative period, unless otherwise noted)2025 Highlights and 2026 Outlook Fourth quarter revenue of $382.2 million increased 17% and full year revenue of $1,424.3 million increased 14%Clinician base increased 9% to 8,040 clinicians, a sequential net increase of 44 in the fourth quarter and 657 for the full yearFourth quarter visit volumes increased 18% to 2.4 million and full year visit volumes increased 14% to 9.0 millionNet income of $11.7 million in the fourth quarter and $9.7 million for the full yearAdjusted EBITDA of $48.8 million in the fourth quarter and $157.7 million for the full yearNet cash provided by operations of $57.6 million in the fourth quarter and $146.2 million for the full yearFree Cash Flow generation of $46.6 million in the fourth quarter and $110.0 million for the full yearFor full year 2026, expecting revenue of $1.615 billion to $1.655 billion, Center Margin of $526 million to $550 million, and Adjusted EBITDA of $185 million to $205 million “2025 was an exceptional year for LifeStance and reflects sustained execution across the organization,” said Dave Bourdon, CEO of LifeStance. “For the full year, we delivered mid-teens revenue growth, positive net income, double-digit Adjusted EBITDA margins and strong cash flow from operations. We closed the year with more than 8,000 clinicians and strong productivity improvement. As we enter 2026, we do so with operating and clinical momentum made possible by the dedication of our employees across the organization. I’m also pleased to announce that our Board of Directors has approved a $100 million share repurchase program, reflecting our strong cash generation and healthy balance sheet which allow us to continue investing for long-term growth while returning capital to shareholders.” Financial Highlights Q4 2025 Q4 2024 Y/Y FY 2025 FY 2024 Y/Y (in millions) Total revenue $382.2 $325.5 17% $1,424.3 $1,251.0 14%Income (loss) from operations 18.1 1.1 NM 24.1 (31.6) NM Center Margin 126.3 109.4 15% 461.1 402.4 15%Net in...